Seeking Alpha

Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis...

Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis (NVS) would be able to develop and commercialize CTIC's Pixuvri cancer drug, which was recently approved by the EU. Should Novartis exercise its option on Pixuvri, the drug giant would owe CTIC a $7.5M license fee, up to $104M in milestone payments, and ongoing royalties.
Comments (3)
  • paulwilliam
    , contributor
    Comments (6) | Send Message
     
    I hope that CTIC can avoid any Dendreon fiascos.
    27 Aug 2012, 01:13 PM Reply Like
  • Mr. Huffington
    , contributor
    Comments (5) | Send Message
     
    Until conditional marketing authorization is lifted, Novartis will remain on the sidelines.
    27 Aug 2012, 04:24 PM Reply Like
  • grateful908
    , contributor
    Comments (44) | Send Message
     
    How much you wanna bet CTIC dilutes the share price with another 85 billion( being sarcastic) cheap shares??? This Co. has to make approx. one BILLION dollars for it's shares to actually be worth anything !!!!! RUN, RUN, from this company !!!!!
    27 Aug 2012, 10:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector